AP2S1

Across TCGA pan-cancer cohorts, AP2S1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of AP2S1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AP2S1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AP2S1 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where AP2S1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AP2S1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.237	<.001	12	view →
LUAD	All	III,IV	−0.421	<.001	9	view →
LSCC	Male	II,III,IV	−0.417	<.001	8	view →
COAD	Male	All	−0.236	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

AP2S1–CCRCC

Open the CCRCC breakdown →